Loading...
Regional therapies are the predominant initial treatment approach for confined, unresectable hepatocellular cancer, but their application may be limited by local tumor size and extent. Investigators from China now report results of a trial in which patients with large hepatocellular cancers were randomized to treatment with hepatic arterial infusion (HAI) of 5-FU, leucovorin, and oxaliplatin every 3 weeks for up to 6 cycles or to transarterial chemoembolization (TACE) with lobaplatin, epirubicin, and lipiodol every 6 weeks. Eligibility criteria included size of the largest liver lesion ≥7 cm.
Of 315 patients, 88% were male, 89% had hepatitis B–related disease, 47% had tumor size >10 cm, and 46% had 1 or 2 lesions. The primary endpoint of ove…